The CIR is committed to finding vaccines to protect infants and children from infectious diseases. The RSVPed team is working in collaboration with the National Institutes of Health to develop a safe and effective RSV vaccine to protect infants and children against respiratory syncytial virus.
Celebrated in the last week of April, World Immunization Week aims to promote the use of vaccines to protect people of all ages against disease. Immunization saves millions of lives every year and is widely recognized as one of the world’s most successful and cost-effective health interventions. Yet, there are still nearly 20 million unvaccinated and under-vaccinated children in the world today.
Please join the Johns Hopkins Vaccine Initiative (JHVI) in the #VaccinesWork challenge. Take a moment to tweet about the importance of vaccines from your social media accounts using the handle @JHUCIR and the hashtag #VaccinesWork. We will tally the tweets and report our success on Vaccine Day!
Each year the Johns Hopkins Vaccine Initiative (JHVI) led by Dr. Ruth A. Karron sponsors a Vaccine Day event to showcase the breadth of vaccine related research by students and faculty at JHSPH and encourage a rich forum for collaborative discussions about future vaccine research being conducted at the school.
Karron has been working with colleagues at the National Institutes of Health on one of several efforts to develop a vaccine. She said she hopes it will be available within the next five to 10 years. A vaccine given to pregnant mothers to protect their babies could be ready sooner. The virus doesn’t evolve much, Karron said, so unlike the flu, which adapts frequently, a vaccine would not have to be updated from year to year.
Dr. Anna P. Durbin presents: The Dengue Human Infection Model: A Critical Tool for Development of a Safe and Effective Vaccine. The lecture will be presented on February 13, 2019 as part of the Johns Hopkins School of Public Health Dean’s Lecture series. Dr. Durbin is an expert in flavivirus vaccine research, leading CIR’s Team FIRE […]
As the world prepares to fight Lassa fever, the interests of pregnant women must be part of the planning
In a First Opinion piece published by STAT News, members of the Pregnancy Research Ethics for Vaccines Epidemics, and New Technologies (PREVENT) working group, including CIR Director Dr. Ruth Karron, speak candidly about the re-emergence of Lassa Fever and it’s potential impact on pregnant and lactating women in affected communities.
Historically, pregnant women have been excluded as potential investigational vaccine recipients during outbreaks, because there is little or no safety data for the unborn fetus. However, the multidisciplinary group of experts that compose PREVENT have re-evaluated the automatic exclusion of pregnant women from vaccine clinical research trials and from the receipt of vaccines in the event of outbreaks like the recent Ebola outbreak in the Congo.